drugset / Trial / NCT00555672

Study Of Sunitinib In Combination With Cisplatin And 5-Fluorouracil In Patients With Advanced Gastric Cancer

NCT00555672

Phase 1 Completed 34 enrolled Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safe and tolerable dose of sunitinib when given together with cisplatin and 5-fluorouracil in patients with advanced gastric cancer who have not received prior chemotherapy for their advanced cancer.

Timeline

Start
2008-08
Primary completion
2009-12
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Sunitinib Small molecule 37.5 mg Oral
Background Cisplatin Other / unclassified 80 mg/m2 Intravenous
Background fluorouracil Small molecule 4000 mg/m2 Other

Indications